Related Experiment Video
Updated: Jan 15, 2026

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
Published on: September 26, 2018
Cardiovascular Risk Factor Management in Medicare Advantage and Traditional Medicare
Andrew S Oseran1,2, Rahul Aggarwal1,3, Rishi K Wadhera1,2,4
1Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA (A.S.O., R.A., R.K.W.).
Insights
Medicare Advantage (MA) and traditional Medicare (TM) beneficiaries show similar rates for managing cardiovascular risk factors like hypertension, diabetes, and hyperlipidemia. This study found no significant differences in treatment or control rates between MA and TM enrollees.
Area of Science:
- Cardiology
- Public Health
- Health Services Research
Background:
- Cardiovascular disease is a leading cause of death among Medicare beneficiaries.
- Management of modifiable cardiovascular risk factors remains suboptimal.
- Medicare Advantage (MA) enrollment is increasing, necessitating an understanding of its quality of care.
Purpose of the Study:
- To compare cardiovascular risk factor management between Medicare Advantage (MA) and traditional Medicare (TM) beneficiaries.
- To evaluate treatment and control rates for hypertension, diabetes, and hyperlipidemia in MA versus TM enrollees.
- To assess the quality of care for cardiovascular risk factors in an expanding MA population.
Main Methods:
- Linked National Health and Nutrition Examination Survey (2015-2018) data with Medicare enrollment data.
- Calculated age- and sex-standardized differences in treatment and control rates for hypertension, diabetes, and hyperlipidemia.
- Utilized National Health and Nutrition Examination Survey weights for nationally representative estimates in adults aged 65+.
Main Results:
- Analyzed 45,426,712 adults (34.4% MA, 65.6% TM).
- Found no significant differences in treatment rates for hypertension, hyperlipidemia, or diabetes between MA and TM beneficiaries.
- Observed similar control rates for hypertension, hyperlipidemia, and diabetes across both MA and TM groups.
Conclusions:
- Treatment and control rates for key cardiovascular risk factors are comparable between MA and TM beneficiaries.
- Despite increased MA enrollment, quality of cardiovascular risk factor management appears consistent across MA and TM.
- Further research may explore reasons for suboptimal risk factor management across all Medicare beneficiaries.
Background:
Although cardiovascular disease is the leading cause of death in the United States among Medicare beneficiaries, management of modifiable risk factors remains suboptimal. Medicare Advantage (MA) enrollment has increased substantially; therefore, understanding the quality of cardiovascular risk factor management in MA is critical. In this study, we evaluated whether cardiovascular risk factor management was better among MA compared with traditional Medicare (TM) beneficiaries.
Methods:
We linked physical examination and laboratory data from the National Health and Nutrition Examination Survey (2015-2018) to Medicare enrollment data. We calculated age- and sex-standardized differences for treatment and control rates of hypertension, diabetes, and hyperlipidemia among adults ≥65 years enrolled in MA compared with TM. National Health and Nutrition Examination Survey weights were used to calculate nationally representative estimates.
Results:
The weighted study population included 45 426 712 adults (34.4% MA, 65.6% TM). The mean age was 72.9 years and 55.3% were female. MA beneficiaries were more likely to be female (58.5% versus 53.5%), less likely to be White (71.7% versus 81.7%), and more likely to have household incomes <100% poverty (11.4% versus 7.0%). Treatment rates for hypertension (82.3% versus 79.1%; SD, 3.4 percentage points [pp]; [95% CI, -1.1 to 7.9]), hyperlipidemia (56.4% versus 56.0%; SD, 0.5 pp [95% CI, -5.7 to 6.8]), and diabetes (76.3% versus 82.5%; SD, -5.0 pp [95% CI, -13.1 to 3.1]) did not significantly differ between MA and TM beneficiaries. There were also no differences in control rates for hypertension (43.6% versus 46.1%; SD, -1.2 pp [95% CI, -8.8 to 6.4]), hyperlipidemia (51.5% versus 48.0%; SD, 4.0 pp [95% CI, -1.7 to 9.7]), and diabetes (61.5% versus 55.3%; SD, 4.4 pp [95% CI, -6.3 to 15.1]).
Conclusions:
Despite the rapid rise in MA enrollment among individuals with cardiovascular risk factors and disease over the past decade, treatment and control rates for hypertension, diabetes, and hyperlipidemia were similar between MA and TM beneficiaries.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease IV: Preventive Measures
Cardiomyopathy V: Interprofessional Care
Atherosclerosis IV: Nursing Management
Heart Failure V: Medical Management
Coronary Artery Disease I: Introduction

